Results 231 to 240 of about 103,862 (301)

PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer. [PDF]

Int J Urol
Okuda Y, Kato T, Ishizuya Y, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Murai J, Nonomura N.   +8 more
europepmc   +1 more source

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer. [PDF]

Ther Adv Med Oncol
Mukherjee UA, Miller RE, Ledermann JA.
europepmc   +1 more source

Anti‐Cancer Effect of a New 5‐FU Derivative Containing Triazole‐Bearing Mannose (5‐FUD‐MAN) Against Human Breast Cancer Cells Through LC3B‐Mediated Cell Death

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 4, April 2026.
The anticancer activity of 5‐FU modified with mannose containing 1,2,3‐triazole compound in MCF‐7 breast cancer cells were revealed in this study. While 5‐FU caused cytotoxicity in both cancerous and healthy cells, 5‐FUD‐Man showed selective cytotoxicity.
Ebru Şanci, Azada Aliyeva, Buket Bakan, Mustafa Özkaraca, Erkan Halay, Kadir Ay, Tamer Karayildirim, N. Ulku Karabay Yavasoglu   +7 more
wiley   +1 more source

Influence of Residual Disease on the Efficacy of PARP Inhibitors in Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta Analysis. [PDF]

Cancers (Basel)
Hwang S, Kim JH, Kim U, Ha HI, Park SY, Lim MC.   +5 more
europepmc   +1 more source

The Flavivirus NS3 Protein: Its Multifaceted Roles and Therapeutic Potential

Journal of Medical Virology, Volume 98, Issue 4, April 2026.
Abstract Mosquito‐borne flaviviruses are important human pathogenic viruses and can cause an array of symptoms ranging from asymptomatic to mild illness but can progress to severe disease conditions. Prominent members of the family Flaviviridae include Dengue virus, Zika virus, and West Nile virus, whose spread has increased globally due to the ...
Haejeong Lee, Hee Cho, Michaela U. Gack
wiley   +1 more source

Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.

JAMA Netw Open
Ostrowski M, Jo Y, Hage Chehade C, Ozay ZI, Gebrael G, Sayegh N, Lin E, Srivastava A, Gordhamer A, Ji R, Li H, Mathew Thomas V, Gupta S, Riaz IB, Maughan BL, Roy S, Agarwal N, Swami U.   +17 more
europepmc   +1 more source

Novel Isoindolinone-Containing PARP Inhibitors: Synthesis and Therapeutic Applications in CNS Cancer Treatment. [PDF]

ACS Med Chem Lett
Zhou X, Liang SH.
europepmc   +1 more source

A Combination of Xanthohumol and Ursolic Acid in the Diet Leads to Synergistic Inhibition of Prostate Cancer Progression

Molecular Carcinogenesis, Volume 65, Issue 4, Page 508-522, April 2026.
ABSTRACT Prostate cancer (PCa) is the second most common cancer and second leading cause of cancer death for American men. Chemoprevention by using phytochemicals offers a promising approach to improve outcomes due to their ability to act on cancer cell metabolism and growth while maintaining low toxicity profiles.
Rachel Clark, Achinto Saha, G. Lavender Hackman, Chelsea A. Friedman, Ruggiero Gorgoglione, Stefano Tiziani, John DiGiovanni   +6 more
wiley   +1 more source